SOX6 and lung adenocarcinoma: The log rank test showed that disease‐related survival (date of diagnosis to the date of cancer‐related death or last follow‐up) of lung adenocarcinoma patients with low SOX6 expression was significantly shorter compared with that of patients with normal levels of SOX6 (median survival, 22.6 versus 36.3 months, respectively; P < 0.001; Fig. 2).